Greef Roderick De Sells 37,795 Shares of BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CEO Greef Roderick De sold 37,795 shares of the stock in a transaction on Wednesday, October 22nd. The shares were sold at an average price of $27.30, for a total value of $1,031,803.50. Following the completion of the sale, the chief executive officer owned 489,998 shares of the company’s stock, valued at $13,376,945.40. The trade was a 7.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

BioLife Solutions Trading Up 0.5%

Shares of BLFS stock opened at $28.79 on Friday. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of -239.90 and a beta of 1.95. BioLife Solutions, Inc. has a 1-year low of $19.10 and a 1-year high of $29.62. The stock’s fifty day simple moving average is $26.11 and its 200-day simple moving average is $23.70.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.31). BioLife Solutions had a positive return on equity of 0.16% and a negative net margin of 5.39%.The business had revenue of $25.42 million for the quarter, compared to analyst estimates of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Hedge Funds Weigh In On BioLife Solutions

Several institutional investors have recently bought and sold shares of BLFS. State of Wyoming boosted its stake in shares of BioLife Solutions by 353.1% during the 1st quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 1,490 shares in the last quarter. US Bancorp DE boosted its position in BioLife Solutions by 243.7% during the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider’s stock worth $49,000 after purchasing an additional 1,528 shares during the period. Ameritas Investment Partners Inc. boosted its position in BioLife Solutions by 12.8% during the second quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock worth $83,000 after purchasing an additional 441 shares during the period. GAMMA Investing LLC grew its holdings in BioLife Solutions by 18.6% during the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider’s stock valued at $96,000 after purchasing an additional 663 shares during the last quarter. Finally, AlphaQuest LLC bought a new position in shares of BioLife Solutions in the second quarter valued at approximately $149,000. 93.24% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BioLife Solutions in a report on Friday. Zacks Research cut BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 7th. HC Wainwright restated a “buy” rating and issued a $32.00 target price (up previously from $30.00) on shares of BioLife Solutions in a research note on Friday, August 8th. Finally, Stephens started coverage on BioLife Solutions in a research note on Tuesday, July 22nd. They set an “overweight” rating and a $30.00 price target for the company. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.29.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.